

May 25, 2020

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Norio Hamada, Chairman of the Board and Chief Executive Officer (CEO), Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Launch of
1 Ingredient / 2 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Chief Executive Officer (CEO), Representative Director: Norio Hamada) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has launched 1 ingredient / 2 products of generic drugs today on May 25, 2020 as below.

New products list

Class	Product Name	Original Brand Name
Long-acting calcium-channel blocker	Azelnidipine Tablets 8mg/16mg “JG”	CALBLOCK TABLETS 8mg/16mg